Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II single-arm study of AZD6094 (Volitinib) plus docetaxel in MET-overexpressing advanced gastric adenocarcinoma as second-line chemotherapy
KCT0004048Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Jul 2017
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of savolitinib, docetaxel in gastric adenocarcinoma, sponsored by AstraZeneca. Started Jul 2017; status: completed.
02
Drugs
savolitinibdocetaxel
03
Conditions
gastric adenocarcinoma
Beyond the preview
Go deeper on KCT0004048.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0004048.